Simone Ciccolone
Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia on tyrosine kinase inhibitors
Rossella Rodia;Giovanni Caocci;Giorgio La Nasa;Olga Mulas;Fernanda Velluzzi;Andrea Loviselli;Stefano Mariotti;Francesco Boi
2021-01-01
Abstract
Abstract Purpose: Thyroid alterations including de novo appearance of thyroid autoimmunity are adverse efects of tyrosine kinase inhibitors, used in solid and hematologic cancer therapy, but the relationship between thyroid alterations during this treatment and the outcome of chronic myeloid leukemia remains unclear. Aim of this study was to investigate whether the presence of thyroid alterations may afect the clinical outcome of chronic myeloid leukemia on tyrosine kinase inhibitors. Methods: We evaluated thyroid function and autoimmunity in 69 chronic myeloid leukemia patients on long-term therapy looking at the association between thyroid abnormalities and disease molecular response. Results: Overall, 24 of 69 (34.8%) had one or more thyroid abnormalities during therapy. A high percentage of patients (21/69, 30.4%) showed thyroid autoimmunity (positive thyroid autoantibodies with ultrasound hypoechogenicity), while clinical and subclinical hypothyroidism and subclinical hyperthyroidism were, respectively, found in 4 of 69 (5.8%) and 3 of 69 (4.3%) of cases. Second-generation tyrosine kinase inhibitors resulted signifcantly associated (14/32, 43.7%) with Hashimoto’s thyroiditis, compared to frst generation (7/37, 18.9%; p=0.03). Interestingly, we also found a signifcant association between euthyroid (14/26, 53.8%) and hypothyroid Hashimoto’s thyroiditis (4/26, 15.4%) in patients with deep molecular response, as compared to euthyroid (3/43, 7%; p=0.0001) and hypothyroid (0/43, 0%; p=0.02) Hashimoto’s thyroiditis patients with major molecular response. Conclusions: Our study confrms and extends our knowledge on the tyrosine kinase inhibitors efects on thyroid, showing that thyroid autoimmunity is frequently observed in chronic myeloid leukemia patients on long-term therapy and is associated with a better oncological response.File | Dimensione | Formato | |
---|---|---|---|
Rodia_et_al-2021-Journal_of_Endocrinological_Investigation.pdf accesso aperto
Descrizione: Articolo principale
Tipologia: versione pre-print
Dimensione 885.41 kB
Formato Adobe PDF
|
885.41 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.